DYAX About
Dyax Dyax therapeutic product candidates
include fully human monoclonal antibodies as well as small proteins and peptides.
Dyax is particularly focused on medical advances in the areas of inflammation
and oncology. Dyax's core proprietary phage display technology allows
the rapid identification of compounds that bind with very high affinity and specificity
to therapeutic targets. Utilizing phage display, they generate large diverse libraries
of human antibodies, peptides, and proteins, which may be screened against disease-associated
target molecules to identify potential binders. Automation allows us them rapidly
screen these libraries for high-affinity binders. Their libraries' vast size and
diversity often yield multiple candidates, from which they can quickly select
the single best therapeutic candidate. Product
Pipeline Discovery Labs Clinical Pipeline Dyax's therapeutic
product pipeline contains fully human monoclonal antibodies, recombinant proteins
and peptides. Dyax already has three clinical development programs involving two
recombinant small proteins. The first, DX-88, is in clinical trials for
the treatment of hereditary angioedema (HAE) in a joint venture with Genzyme Corporation.
It is also being evaluated by Dyax alone in clinical trials for use during on-pump
open heart surgery (CABG). DX-890, Dyax's second compound in clinical
development, is being evaluated by Dyax's collaborator Debiopharm SA for the treatment
of cystic fibrosis (CF). More
on Dyax Key
Statistics for Dyax
Basic
Chart for Dyax